Shanghai Kehua Bio-Engineering Co.,Ltd (002022.SZ)
002022.SZ Stock Price Chart
Explore Shanghai Kehua Bio-Engineering Co.,Ltd interactive price chart. Choose custom timeframes to analyze 002022.SZ price movements and trends.
002022.SZ Company Profile
Discover essential business fundamentals and corporate details for Shanghai Kehua Bio-Engineering Co.,Ltd (002022.SZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
21 Jul 2004
Employees
2.15K
Website
https://www.skhb.comCEO
Ming Li
Description
Shanghai Kehua Bio-Engineering Co.,Ltd researches and develops, produces, and sells in vitro diagnostic products in China. The company offers HBV, hepatitis B, HCV antibody, alpha fetoprotein quantitative, and fecal occult blood test kits; carcino-embryonic antigen quantitative determination kits; test kits for antibody to treponema pallidum and human immunodeficiency virus, and the five serological markers of hepatitis B; and diagnostic kit for syphilis rapid plasma regain. It also provides automatic biochemical analysis systems for clinical laboratories and medical institutions; nucleic acid blood screening systems; automatic chemiluminescence measuring systems; microplate readers and plate washers; general and dedicated reagent packaging systems; and electrolyte analyzers. In addition, the company researches and develops diagnostic products in the field of renal disease that provides screening diagnosis and therapeutic effect monitoring solutions for patients with various types of kidney disease. Further, it offers single-part and multi-part nucleic acid detection, and enzyme immunoassay analysis systems; reagents for blood collection agencies and clinical diagnosis; and laboratory diagnostic instruments. Additionally, the company distributes automatic chemiluminescence, microbial, and blood and urine analysis systems, as well as their supporting supplies; and automatic biochemical analyzers and other products. It also establishes third-party medical laboratory centers; provides planning and designing, management consulting, equipment and reagent supplying, and supply chain optimization services for medical laboratories, as well as medical testing services. In addition, the company is involved in the social medical undertakings. It also exports its Kehua-branded products to 38 countries and regions. The company was founded in 1981 and is based in Shanghai, the People's Republic of China.
002022.SZ Financial Timeline
Browse a chronological timeline of Shanghai Kehua Bio-Engineering Co.,Ltd corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 31 Mar 2025
EPS came in at -¥0.10 , while revenue for the quarter reached ¥387.88M .
Earnings released on 31 Dec 2024
EPS came in at -¥1.03 , while revenue for the quarter reached ¥408.97M .
Earnings released on 29 Sept 2024
EPS came in at -¥0.14 , while revenue for the quarter reached ¥441.70M .
Earnings released on 30 Jun 2024
EPS came in at -¥0.05 , while revenue for the quarter reached ¥465.22M .
Earnings released on 19 Apr 2024
EPS came in at -¥0.06 , while revenue for the quarter reached ¥443.30M .
Earnings released on 20 Mar 2024
EPS came in at -¥0.42 , while revenue for the quarter reached ¥519.40M .
Earnings released on 30 Sept 2023
EPS came in at -¥0.08 , while revenue for the quarter reached ¥507.75M .
Earnings released on 30 Jun 2023
EPS came in at -¥0.07 , while revenue for the quarter reached ¥563.33M .
Dividend declared on 10 May 2023
A dividend of ¥0.60 per share was announced, adjusted to ¥0.60. The dividend was paid on 10 May 2023.
Earnings released on 31 Mar 2023
EPS came in at ¥0.19 , while revenue for the quarter reached ¥833.15M .
Earnings released on 31 Dec 2022
EPS came in at -¥0.38 , while revenue for the quarter reached ¥1.59B .
Earnings released on 30 Sept 2022
EPS came in at ¥3.63 , while revenue for the quarter reached ¥4.48B .
Dividend declared on 19 Jul 2022
A dividend of ¥0.07 per share was announced, adjusted to ¥0.07. The dividend was paid on 19 Jul 2022.
Earnings released on 30 Jun 2022
EPS came in at ¥0.07 , while revenue for the quarter reached ¥482.43M .
Earnings released on 29 Apr 2022
EPS came in at ¥0.06 falling short of the estimated ¥0.13 by -51.07%, while revenue for the quarter reached ¥420.50M , missing expectations by -39.66%.
Earnings released on 26 Apr 2022
EPS came in at ¥0.39 , while revenue for the quarter reached ¥1.13B .
Earnings released on 29 Oct 2021
EPS came in at ¥0.49 surpassing the estimated ¥0.13 by +288.60%, while revenue for the quarter reached ¥1.33B , beating expectations by +90.54%.
Dividend declared on 16 Jul 2021
A dividend of ¥0.20 per share was announced, adjusted to ¥0.20. The dividend was paid on 16 Jul 2021.
Earnings released on 30 Jun 2021
EPS came in at ¥0.27 surpassing the estimated ¥0.13 by +112.67%, while revenue for the quarter reached ¥946.76M , beating expectations by +35.85%.
Earnings released on 7 Apr 2021
EPS came in at ¥0.57 , while revenue for the quarter reached ¥1.45B .
Earnings released on 31 Dec 2020
EPS came in at ¥0.53 surpassing the estimated ¥0.12 by +341.03%, while revenue for the quarter reached ¥1.59B , beating expectations by +144.33%.
Earnings released on 28 Oct 2020
EPS came in at ¥0.41 surpassing the estimated ¥0.12 by +240.53%, while revenue for the quarter reached ¥1.11B , beating expectations by +70.35%.
002022.SZ Stock Performance
Access detailed 002022.SZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.